For instance, EZH2 inhibition by GSK343 and UNC1999 demonstrates anti-myeloma activity by reducing the survival of MM cell lines and CD138+ MM cells isolated from newly diagnosed patients [58,102,112]. This evidence concerns the gene SDC1 and plasma cell myeloma.